Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
暂无分享,去创建一个
O. Olopade | T. Rebbeck | R. Eeles | B. Weber | L. J. van 't Veer | D. Evans | J. Garber | C. Isaacs | S. Neuhausen | S. Domchek | A. Eisen | S. Narod | K. Armstrong | H. Lynch | G. Tomlinson | M. Daly | T. Wagner | T. Friebel | E. Matloff | L. J. van ‘t Veer | D. G. Evans | L. J. van ’t Veer | Barbara L. Weber | S. A. Narod | Judy Garber | Henry T. Lynch | D. Gareth Evans | Barbara L. Weber | D. G. Evans
[1] M. King,et al. Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2 , 2003, Science.
[2] J. Satagopan,et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. , 2002, The New England journal of medicine.
[3] J. Satagopan,et al. Risk of endometrial carcinoma associated with BRCA mutation. , 2001, Gynecologic oncology.
[4] B. Karlan. Defining cancer risks for BRCA germline mutation carriers: implications for surgical prophylaxis. , 2004, Gynecologic oncology.
[5] B. Weber,et al. Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. , 2004, Journal of Clinical Oncology.
[6] G. Rennert,et al. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma. , 2004, Gynecologic oncology.
[7] E. Negri,et al. Hysterectomy, Oophorectomy in Premenopause, and Risk of Breast Cancer , 1997, Obstetrics and gynecology.
[8] Charles Kooperberg,et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.
[9] T. Rebbeck,et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. , 2002, Journal of the National Cancer Institute.
[10] D. Schaid,et al. Prophylactic mastectomy for BRCA1/2 carriers: progress and more questions. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] K. Heimdal,et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study , 2000, The Lancet.
[12] R. Langer,et al. Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women: The Women's Health Initiative Randomized Trial , 2003 .
[13] O. Olopade,et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. , 1999, Journal of the National Cancer Institute.
[14] B. V. VON Schoultz,et al. Elective ovarian removal and estrogen replacement therapy--effects on sexual life, psychological well-being and androgen status. , 1993, Journal of psychosomatic obstetrics and gynaecology.
[15] C K Redmond,et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.
[16] Douglas F Easton,et al. Cancer Incidence in BRCA1 mutation carriers. , 2002, Journal of the National Cancer Institute.
[17] P. Hartge,et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. , 1997, The New England journal of medicine.
[18] M. Pike,et al. Hormonal chemoprevention of cancer in women , 1993, Science.
[19] John Robbins,et al. National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section , 2004, BMJ : British Medical Journal.
[20] R. Hoover,et al. Menstrual factors and risk of breast cancer. , 1988, Cancer investigation.
[21] F. V. van Leeuwen,et al. Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation. , 2003, Journal of the National Cancer Institute.
[22] D. Easton,et al. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. , 1995, American journal of human genetics.
[23] Susan L Neuhausen,et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. , 2002, The New England journal of medicine.
[24] S. Wacholder. Bias in intervention studies that enroll patients from high-risk clinics. , 2004, Journal of the National Cancer Institute.
[25] V. Beral,et al. Evidence from randomised trials on the long-term effects of hormone replacement therapy , 2002, The Lancet.
[26] K. Kerlikowske,et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. , 1995, Obstetrics and gynecology.
[27] Valerie Beral,et al. Breast cancer and hormone-replacement therapy in the Million Women Study , 2003, The Lancet.